Gilead Moves On From Selonsertib, Looks To ATLAS To Map Its NASH Future

 
• By Joseph Haas

Gilead detailed its Phase III failure with ASK1 inhibitor selonsertib in NASH, but anticipates finding a new regimen to take into Phase III in NASH with the ATLAS combination study data expected in December.

Gilead, Liver Meeting stage
Gilead presents the full Phase III dataset for selonsertib at AASLD 2019

More from Clinical Trials

More from R&D